{"id":"mithramycin","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT02859415","NCT01624090","NCT01610570"],"aliases":["Mithracin","Plicamycin"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"aiSummary":"","brandName":"Mithramycin","companyId":"national-cancer-institute-nci","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"Small molecule","drugClass":"","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"National Cancer Institute (NCI)","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"},{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"Mithramycin","indications":{"approved":[{"name":"Malignant tumor of testis","diseaseId":"malignant-tumor-of-testis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT02859415","phase":"Phase 1","title":"Phase I/II Evaluation of Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in Patients With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ ","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":3,"indication":"Esophageal Neoplasms, Lung Neoplasms","completionDate":"2021-12-01"},{"nctId":"NCT01624090","phase":"Phase 2","title":"Phase II Evaluation of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":16,"indication":"Lung Cancer, Esophageal Cancer","completionDate":"2019-09-27"},{"nctId":"NCT01610570","phase":"Phase 1","title":"Phase I/II Trial of Mithramycin in Children and Adults With Refractory Extracranial Solid Tumors (Phase I) or Ewing Sarcoma and EWSFLI1 Fusion Transcript (Phase II)","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":8,"indication":"Ewing Sarcoma, Sarcoma","completionDate":"2014-05-21"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":3},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}